Physician profile
Paul A Rich
NPI 1528060217
$4,474.77
in general payments reported to CMS, 2019-2025
32 companies · $66.19 in 2025
The $66.19 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,495 · 2020: $40.90 · 2021: $1,698 · 2022: $311 · 2023: $397 · 2024: $466 · 2025: $66.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $930.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $930.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $1,545.29 | 2019-2024 | Gardasil 9, Vaxneuvance, Verquvo |
| Organon LLC | $1,375.00 | 2021 | |
| Abbvie INC. | $211.74 | 2021-2025 | |
| Novo Nordisk INC | $142.17 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Abbott Laboratories | $123.74 | 2022-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $104.16 | 2019-2021 | |
| Lilly USA, LLC | $95.80 | 2023-2025 | Jardiance, Zepbound, Emgality |
| Amgen INC. | $92.80 | 2020-2024 | Krystexxa |
| Astellas Pharma US INC | $81.55 | 2019-2024 | Veozah, Myrbetriq |
| Astrazeneca Pharmaceuticals LP | $71.88 | 2019-2024 | Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $66.59 | 2022-2024 | Arexvy, Trelegy Ellipta, Bexsero |
| Pfizer INC. | $63.23 | 2023-2024 | |
| Exact Sciences Corporation | $55.77 | 2023-2024 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $54.13 | 2022-2023 | |
| Amarin Pharma, INC. | $48.78 | 2020-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $36.19 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $33.71 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.20 | 2022 | |
| Boston Scientific Corporation | $30.45 | 2023 | Watchman Access System, Rezum Generator |
| Sanofi Pasteur INC. | $29.11 | 2021-2022 | |
| Nevro Corp. | $26.15 | 2022 | |
| Agile Therapeutics, INC. | $23.23 | 2024 | Twirla |
| Evoke Pharma, INC. | $16.79 | 2025 | |
| Currax Pharmaceuticals LLC | $15.82 | 2021 | |
| Shield Therapeutics INC | $15.70 | 2023 | Accrufer |
| Sanofi-Aventis U.S. LLC | $13.55 | 2021 | |
| Hologic Sales and Service, LLC | $12.87 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $12.29 | 2021 | |
| Sunovion Pharmaceuticals INC. | $11.69 | 2022 | |
| Therapeuticsmd, INC. | $11.17 | 2021 | |
| Sumitomo Pharma America, INC. | $10.12 | 2023 | Gemtesa |
| Takeda Pharmaceuticals U.S.A., INC. | $10.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Rich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.